- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: Oral azacitidine
Total 8953 results
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Merck Sharp & Dohme LLC; Celgene CorporationCompletedColorectal CancerUnited States
-
The Hospital for Sick ChildrenCompletedChildhood Solid Tumor | Recurrent Childhood CNS Tumor | Ependymoma, Recurrent ChildhoodUnited States, Canada, Australia
-
The University of Texas Health Science Center,...CompletedBrain Tumor RecurrentUnited States
-
French Innovative Leukemia OrganisationAcute Leukemia French AssociationRecruitingAML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITDFrance
-
Shenzhen Second People's HospitalRecruitingAcute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaChina
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Chronic Myelomonocytic Leukemia-0United States
-
University of FlorenceActive, not recruiting
-
Kirby InstituteCelgeneActive, not recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaAustralia
-
CelgeneCompletedNasopharyngeal NeoplasmsCanada, United States, Taiwan, France, Spain, Greece, Italy, Singapore, Tunisia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1United States
-
Bristol-Myers SquibbRecruiting
-
CelgeneCompletedMyelodysplastic Syndromes | Leukemia, Myeloid, AcuteUnited States, United Kingdom
-
SymBio PharmaceuticalsWithdrawnMyelodysplastic SyndromeJapan
-
Yale UniversityBristol-Myers Squibb; National Cancer Institute (NCI)WithdrawnAcute Myeloid LeukemiaUnited States
-
CelgeneActive, not recruitingNeoplasms | Hematologic Malignancies | Hematologic NeoplasmUnited Kingdom, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterTerminatedLeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.RecruitingAcute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Hematologic and Lymphocytic Disorder | Acute Myeloid Leukemia in Remission | FLT3 Gene Mutation | Minimal Residual Disease PersistenceUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.RecruitingRecurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute LeukemiaUnited States
-
University of OklahomaCelgene CorporationTerminatedPancreatic CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
CelgeneCompletedMyelodysplastic SyndromesUnited States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); CelgeneRecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated CellsUnited States
-
National Cancer Institute (NCI)WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic SyndromeUnited States
-
CelgeneCompletedMyelodysplastic SyndromeUnited States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
-
M.D. Anderson Cancer CenterCelgene CorporationCompletedLeukemiaUnited States
-
National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterCelgeneCompleted
-
Carlos Graux, MD, PhDCelgene Corporation; Belgian Hematological SocietyCompletedMyelodysplastic Syndrome | Acute Myelogenous LeukemiaBelgium
-
Celyad Oncology SAWithdrawnMyelodysplastic Syndromes | AML, Adult
-
Universitätsklinikum Hamburg-EppendorfCompletedChronic Myelomonocytic Leukemia | Myelodysplastic SyndromeGermany
-
National Institute of Diabetes and Digestive and...Completed
-
M.D. Anderson Cancer CenterKura Oncology, Inc.Not yet recruitingRefractory Acute Leukemia | Pediatric RelapsedUnited States
-
Translational Research in OncologyCelgeneTerminatedEpithelial Ovarian CancerUnited States
-
Columbia UniversityCelgeneTerminatedLymphoma | Hodgkin Lymphoma | Lymphoid Malignancies | Non-hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterHiberCell, Inc.Not yet recruitingAcute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterBayerCompleted
-
M.D. Anderson Cancer CenterAriad PharmaceuticalsWithdrawnLeukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
-
Beijing 302 HospitalNot yet recruitingRefractory Acute Myeloid Leukemia | Minimal Residual Disease | Relapsed Acute Myeloid Leukemia
-
Brian JonasNational Cancer Institute (NCI); GlycoMimetics IncorporatedRecruitingUproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaAcute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Recurrent Myeloproliferative NeoplasmUnited States
-
Weill Medical College of Cornell UniversityMerck Sharp & Dohme LLC; CelgeneCompleted
-
New Mexico Cancer Care AllianceCompletedAdvanced Solid Tumor MalignanciesUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditionsUnited States
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative NeoplasmUnited States
-
University of VirginiaRecruitingLymphoma, T-CellUnited States